KRAS and neoplasm: There was no significant association between mOS and gender, tumor location, mucinous histology, number of metastatic sites or KRAS mutations status, while a non significant trend has been observed for improved survival in patients younger than 65 years of age (32.3 vs. 27.8 months; HR: 0.82, 95% CI: 0.61-1.04; p=0.07) compared to those over 65 years of age (Table 1).